P-Tabletten weiß 7 mm Lichtenstein
Sponsors
CGBS GbR, Charite Universitaetsmedizin Berlin KöR, Medical Center - University Of Freiburg, Universitaetsmedizin Goettingen, University Medical Center Hamburg-Eppendorf
Conditions
Alport syndromeHealthy volunteersIdiopathic pulmonary fibrosisInflammatory or autoimmune disordersLiver cirrhosisNewly diagnosed acute myeloid leukemia (AML)NonePatients with acute unilateral vestibulopathy (AUVP)
Phase 2
Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in post-COVID-19 syndrome (PCS) - PoCoVIT
CompletedCTIS2023-504826-21-00
Start: 2024-07-02End: 2025-03-25Target: 418Updated: 2024-11-13
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)
RecruitingCTIS2024-514457-30-00
Start: 2024-02-26Target: 90Updated: 2024-08-26
L-Thyroxine for the treatment of acute unilateral vestibulopathy (AUVP): a monocentric, double-blind, placebo-controlled trial (T4U)
Not yet recruitingCTIS2024-519515-34-00
Target: 48Updated: 2026-04-02
Safety and Tolerability of systemic administration of metformin in patients with Idiopathic Pulmonary Fibrosis (IPF): A randomized, placebo-controlled, double-blind, phase II proof-of-concept study (Met_for_IPF)
Not yet recruitingCTIS2025-523341-10-00
Target: 40Updated: 2026-09-30
Phase 3
DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dapagliflozin on the progression of chronic kidney disease in adolescent and young adult patients with Alport syndrome
RecruitingCTIS2023-508502-18-00
Start: 2024-03-19Target: 102Updated: 2025-10-16
Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a doubleblind, placebo-controlled trial (STOPPIT)
RecruitingCTIS2023-509863-26-00
Start: 2021-04-29Target: 476Updated: 2025-06-24
The effects of the manipulation of 5-HT, DA and NA on exercise-induced fatigue and brain activation
Not yet recruitingCTIS2024-514038-19-00
Target: 59Updated: 2024-08-29
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy - DECIDER-2 trial
RecruitingCTIS2023-507461-26-00
Start: 2022-09-22Target: 256Updated: 2026-01-19
Phase 4
Randomised, placebo-controlled clinical trial on the efficacy of Roleca® juniper 100 mg for dyspeptic digestive complaints such as cramps in the gastrointestinal tract, flatulence and bloating.
CompletedCTIS2023-504750-35-01
Start: 2023-10-24End: 2025-02-20Target: 100Updated: 2024-11-05
Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: a randomized controlled multicenter trial
RecruitingCTIS2024-517334-18-00
Start: 2022-04-06Target: 25Updated: 2026-01-14
Ergogenic effects of pseudoephedrine on edurance performance in relation to the determination of threshold values in urine and capillary and venous blood
RecruitingCTIS2024-513810-36-00
Start: 2025-08-27Target: 30Updated: 2025-09-18